191 related articles for article (PubMed ID: 21455766)
1. Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families.
Pasanisi P; Bruno E; Venturelli E; Manoukian S; Barile M; Peissel B; De Giacomi C; Bonanni B; Berrino J; Berrino F
Fam Cancer; 2011 Sep; 10(3):521-8. PubMed ID: 21455766
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
Jernström H; Sandberg T; Bågeman E; Borg A; Olsson H
Int J Gynecol Cancer; 2006; 16 Suppl 2():497. PubMed ID: 17010055
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of diet and physical activity in BRCA mutation carriers.
Pasanisi P; Bruno E; Manoukian S; Berrino F
Fam Cancer; 2014 Jun; 13(2):181-7. PubMed ID: 24162448
[TBL] [Abstract][Full Text] [Related]
4. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
Jernström H; Sandberg T; Bågeman E; Borg A; Olsson H
Br J Cancer; 2005 Mar; 92(5):857-66. PubMed ID: 15756256
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark.
Kalledsøe L; Dragsted LO; Hansen L; Kyrø C; Grønbæk H; Tjønneland A; Olsen A
Growth Horm IGF Res; 2019 Feb; 44():33-42. PubMed ID: 30622040
[TBL] [Abstract][Full Text] [Related]
7. Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Mahdavi M; Nassiri M; Kooshyar MM; Vakili-Azghandi M; Avan A; Sandry R; Pillai S; Lam AK; Gopalan V
J Cell Physiol; 2019 May; 234(5):5741-5750. PubMed ID: 30552672
[TBL] [Abstract][Full Text] [Related]
8. Prospective multicenter cohort study of estrogen and insulin-like growth factor system in BRCA mutation carriers.
Kim J; Johnson L; Skrzynia C; Buchanan A; Gracia C; Mersereau JE
Cancer Causes Control; 2015 Aug; 26(8):1087-92. PubMed ID: 26006218
[TBL] [Abstract][Full Text] [Related]
9. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
10. Oral contraceptive use and BRCA penetrance: a case-only study.
Pasanisi P; Hédelin G; Berrino J; Chang-Claude J; Hermann S; Steel M; Haites N; Hart J; Peled R; Gafà L; Leggio L; Traina A; Amodio R; Primic-Zakelj M; Zadnik V; Veidebaum T; Tekkel M; Berrino F
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2107-13. PubMed ID: 19549808
[TBL] [Abstract][Full Text] [Related]
11. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study.
Kim SJ; Zhang CXW; Demsky R; Armel S; Kim YI; Narod SA; Kotsopoulos J
Breast Cancer Res Treat; 2019 Apr; 174(3):741-748. PubMed ID: 30603998
[TBL] [Abstract][Full Text] [Related]
13. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
[TBL] [Abstract][Full Text] [Related]
14. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
[TBL] [Abstract][Full Text] [Related]
15. Low penetrance alleles as risk modifiers in familial and sporadic breast cancer.
Esteban Cardeñosa E; de Juan Jiménez I; Palanca Suela S; Chirivella González I; Segura Huerta A; Santaballa Beltran A; Casals El Busto M; Barragán González E; Fuster Lluch O; Bermúdez Edo J; Bolufer Gilabert P
Fam Cancer; 2012 Dec; 11(4):629-36. PubMed ID: 22926736
[TBL] [Abstract][Full Text] [Related]
16. Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort.
Zeinomar N; Phillips KA; Daly MB; Milne RL; Dite GS; MacInnis RJ; Liao Y; Kehm RD; Knight JA; Southey MC; Chung WK; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; ; Andrulis IL; Buys SS; John EM; Hopper JL; Terry MB
Int J Cancer; 2019 Jul; 145(2):370-379. PubMed ID: 30725480
[TBL] [Abstract][Full Text] [Related]
17. The Role of Circulating Adiponectin and SNP276G>T at
Daniele A; Paradiso AV; Divella R; Digennaro M; Patruno M; Tommasi S; Pilato B; Tufaro A; Barone M; Minoia C; Colangelo D; Savino E; Casamassima P; Bruno E; Oliverio A; Pasanisi P
Cancer Genomics Proteomics; 2020; 17(3):301-307. PubMed ID: 32345671
[TBL] [Abstract][Full Text] [Related]
18. rs15869 at miRNA binding site in BRCA2 is associated with breast cancer susceptibility.
Cao J; Luo C; Yan R; Peng R; Wang K; Wang P; Ye H; Song C
Med Oncol; 2016 Dec; 33(12):135. PubMed ID: 27807724
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
Krajcik RA; Borofsky ND; Massardo S; Orentreich N
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
